Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
North Eastern Germany Society of Gynaecologic Oncology |
---|---|
Information provided by: | North Eastern Germany Society of Gynaecologic Oncology |
ClinicalTrials.gov Identifier: | NCT00170625 |
Compatibility of the topotecan therapy in combination with carboplatin.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer |
Drug: Hycamtin |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Multicenter, Prospective Phase-I/II-Study: Topotecan and Carboplatin in the Therapy of Patients With Relapsed Ovarian Cancer |
Estimated Enrollment: | 36 |
Study Start Date: | June 2004 |
Estimated Study Completion Date: | September 2010 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 310300 |
Study First Received: | September 9, 2005 |
Last Updated: | April 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00170625 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
platin-resistant |
Genital Diseases, Female Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases |
Urogenital Neoplasms Carboplatin Endocrinopathy Ovarian Diseases Topotecan Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Pharmacologic Actions Adnexal Diseases |